Actuate is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutic agents for patients with cancer or inflammatory diseases.
Actuate aims to give patients with hard-to-treat cancers the opportunity to live longer and better through a best-in-class agent with the potential capacity to slow, stop, or shrink tumors, with minimal adverse effects.
Actuate was founded in 2015 by Dan Schmitt and Andrew Mazar. The company is headquartered in Fort Worth, Texas, with an office in Dublin, Ireland.
Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets multiple molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy.
Elraglusib has shown tremendous potential in the treatment of many different cancers when used alone or in combination with other types of cancer therapies, including chemotherapy and immune modulators such as checkpoint inhibitors.
Actuate Therapeutics is backed by Kairos Ventures, Bios Partners, DEFTA Partners, Tech Coast Angels, and others. The company raised $11.2M in a new financing round on Oct 24, 2022. This brings Actuate's total funding to $56.9M to date.